Wednesday - March 18, 2026

Category Archives: Science

Diabetic Macular Edema Treatment Pipeline Shows Strong Momentum as 45+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Diabetic Macular Edema Pipeline Insight 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Diabetic Macular Edema pipeline landscape. It covers the Diabetic Macular Edema pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Diabetic Retinopathy Clinical Trial Pipeline Expands as 50+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Diabetic Retinopathy Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Dry Eye Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s “Dry Eye Disease Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 60+ pipeline drugs in the Dry Eye Disease pipeline landscape. It covers the Dry Eye Disease pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Cystic Fibrosis Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Cystic fibrosis Pipeline Insight, 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Cystic fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline Gains Momentum: 45+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Cyclin-Dependent Kinase Inhibitor Pipeline Insights 2026” report provides comprehensive insights about 45+ companies and 52+ pipeline drugs in Cyclin-Dependent Kinase Inhibitor pipeline landscape. It covers the Cyclin-Dependent Kinase Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Infection Control Market Size, Share & Growth Forecast to 2030

Infection Control Market by Product (Sterilization Equipment: Hydrogen Peroxide, Ethylene, Radiation), Service (ETO, Gamma, E-Beam), Disinfection (Wipes, Disinfector), Gown, Mask, Endoscope Reprocessing, End User (Hospital, Pharma) – Global Forecast to 2030 According to MarketsandMarkets™, The report ” Infection Control Market … Continue reading →

Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Gains Momentum: 65+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Chronic Obstructive Pulmonary Disease Pipeline Insight 2026” report provides comprehensive insights about 65+ companies and 70+ pipeline drugs in the Chronic Obstructive Pulmonary Disease pipeline landscape. It covers the Chronic Obstructive Pulmonary Disease pipeline drug profiles, including clinical and … Continue reading →

Hidradenitis Suppurativa Market is Predicted to Cross USD 7 Billion by 2036 Owing to the Robust Pipeline Development | DelveInsight

The growth of the hidradenitis suppurativa market is expected to be mainly driven by rising awareness and access to treatment, as well as robust pipeline activity comprising promising therapies such as Eltrekibart (Eli Lilly), Lutikizumab (AbbVie), Sonelokimab (MoonLake Immunotherapeutics), Brepocitinib … Continue reading →

Autosomal Dominant Polycystic Kidney Disease Market Set for Robust Growth by 2034 Amid Advancing Therapeutics Landscape | DelveInsight

The dynamics of the autosomal dominant polycystic kidney disease market are anticipated to change in the coming years, owing to the launch of emerging therapies such as XRx-008 (Xortx Therapeutics), CYX082 (Novartis), AZD1613 (AstraZeneca), VX-407 (Vertex Pharmaceuticals), ABBV-CLS-628 (Calico Life … Continue reading →